Clearmind Medicine Initiates Phase I/IIa AUD Trial at Yale, Multiple Sites

Clearmind Medicine has launched its U.S. clinical trial operations for its Phase I/IIa study targeting Alcohol Use Disorder (AUD) by activating all planned trial sites, including Yale School of Medicine, Johns Hopkins University, and Israel’s IMCA Center. The company has secured all required approvals from the FDA and Institutional Review Boards, deployed its Electronic Data Capture system, and imported its drug candidate, CMND-100, into the United States. With these preparations complete, patient enrollment can now begin. The trial will be led at Yale by Dr. Anahita Bassir Nia and aims to address the significant public health challenge posed by alcoholism, with Clearmind’s CEO highlighting the urgent need for more effective treatments. This milestone is considered a crucial step toward potentially transforming the treatment landscape for AUD. The study’s collaboration with prominent institutions underlines its potential impact.